Targeted therapeutics, such as phosphate binders and vitamin D receptor agonists, can aid in treating CKD-induced secondary hyperparathyroidism by reducing serum phosphate levels and increasing osteopontin levels, which regulate bone remodeling [33,34,35]. Here, SPP1 is linked to secondary hyperparathyroidism.